Compare HEQ & ELDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HEQ | ELDN |
|---|---|---|
| Founded | 2011 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 133.9M | 123.1M |
| IPO Year | N/A | N/A |
| Metric | HEQ | ELDN |
|---|---|---|
| Price | $10.98 | $2.03 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 43.1K | ★ 891.4K |
| Earning Date | 01-01-0001 | 11-14-2025 |
| Dividend Yield | ★ 9.78% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.08 | $1.35 |
| 52 Week High | $11.84 | $4.97 |
| Indicator | HEQ | ELDN |
|---|---|---|
| Relative Strength Index (RSI) | 62.00 | 66.58 |
| Support Level | $10.77 | $1.70 |
| Resistance Level | $10.88 | $1.76 |
| Average True Range (ATR) | 0.11 | 0.11 |
| MACD | 0.03 | 0.07 |
| Stochastic Oscillator | 69.14 | 95.90 |
John Hancock Hedged Equity & Income Fund is a closed-end management investment company. Its investment objective is to provide total return with a focus on current income and gains and also consisting of long-term capital appreciation. It invests in various sectors such as financials, consumer discretionary, information technology, energy, healthcare, materials, real estate, consumer staples, short-term investments, and others.
Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets the CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and patients living with ALS. The company's compound in development is tegoprubart, an IgG1, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential.